In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angeion Corp.

Latest From Angeion Corp.

B. Braun's Bet on Balloons

Until now, B. Braun, one of the oldest players in cardiovascular devices, has been comfortable in its niche. B. Braun's cardiovascular business is actually made up of two units, one that makes products for interventional radiologists and surgeons in the peripheral field, the other on a range of devices used in interventional cardiology. But the investment the company is making in a new technology, drug-eluting balloons, could be disruptive, if not to interventional cardiology, at least to the cardiovascular device companies and none more so than B. Braun itself.
Medical Device Platform Technologies

The Rich Get Richer

Cash is king and the more you've got, the more investors are willing to give. At least that's the message in medical devices. Start-Up examined recent private offerings of public medical device companies to see if there was a relationship between the cash a company had and the valuation new private investors were willing to afford the company.
Medical Device Business Strategies

Industry Outlook 1999/Fund Managers

Are small-cap stocks stuck in a temporary down cycle? Or are they being hurt by structural changes in the investment community? True, investment funds have increased in size to such a degree that it has become financially impossible for most of them to invest in small cap companies. But small companies have things that large companies don't--innovative and differentiable products that are so crucial to the growth of large companies. {IN VIVO} talks with top-ranked health care analyst Dan LeMaitre of Cowen & Co. about the pressures on large and small device companies.
Medical Device Strategy

Angeion: Life After St. Jude

Angeion thought it was going to get to the implantable defibrillator market with St. Jude as a marketing partner. But St. Jude's acquisition of Ventritex changed all that. Now, Angeion is going it alone, with worldwide royalty-free licenses from St. Jude on a wide range of patents. But can Angeion use that base and what company officials believe is superior technology to succeed in a market increasingly dominated by giants?
Medical Device Strategy
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Therapeutic Areas
  • Cardiovascular
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Angeion Corp.
  • Senior Management
  • Gregg O Lehman, PhD, Pres. & CEO
    Rob Wolf, CFO
    Michael J Kallok, PhD, VP, Research & Reg. Affairs
    William Rissmann, VP, Product Dev.
    Todd M Austin, EVP, Global Mktg. & Corp. Strategy
  • Contact Info
  • Angeion Corp.
    Phone: (612) 315-2000
    7601 Northland Dr.
    Minneapolis, MN 55428-1088